by Wyn Staheli, Director of Content - innoviHealth
Jan 11th, 2021
In a highly unusual, but anticipated move, new ICD-10-CM codes took effect on January 1, 2021. Rarely have ICD-10-CM codes been released in January, but as you may have guessed, these changes are in relation to COVID-19. It should be noted that there were also codes added to the ICD-10-PCS code set. See the end of this article for a list of those new codes. The following information will help your organization understand these changes.
Pneumonia due to Coronavirus Disease 2019 (COVID-19)
The Federal Drug Administration (FDA) requested a new code for pneumonia due to COVID-19 to enable tracking of this condition instead of reporting the other viral-associated pneumonia code. Interim coding guidance required the reporting of two separate diagnosis codes, one for COVID-19 and the other for ‘other viral pneumonia.’ According to their application:
“... the investigation using CMS data suggest that using two codes may substantially under record pneumonia-related COVID-19, with <50% of recorded COVID-19 cases having had ‘other viral pneumonia’ recorded. Also, CDC COVID-19 mortality data shows that less than 50% of COVID-related deaths have pneumonia recorded, suggesting a potentially substantial under-recording of pneumonia due to COVID-19. As such, the introduction of the specific code for pneumonia, including geographic distribution and severity of pneumonia-related cases, and will help to develop prevention strategies and assure public health safety in the U.S. The new code will also allow to distinguish the pneumonia due to COVID-19 from the previously approved SARS-associated pneumonia code and from other viral pneumonia code(s) and thus will improve accuracy of diagnosis and coding.”
The new code is:
J12.82 Pneumonia due to coronavirus disease 2019
Pneumonia due to COVID-19
Pneumonia due to 2019 novel coronavirus (SARS-CoV-2)
Multisystem Inflammatory Syndrome (MIS)
The news has kept us informed about this complex, severe condition which has been linked to COVID-19 in both children and adults. This condition is not unique to COVID, therefore a new code was needed to track this complication when it is COVID-related. Although there was some discussion about creating a code for both the adult and child versions, at this time they only added a code for multisystem inflammatory syndrome in children (MIS-C).
According to the CDC Health Advisory, this condition is defined as follows:
- An individual aged less than 21 years of age presenting with fever1, laboratory evidence of inflammation2, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
1Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours
2Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin
The new code for this condition (M35.81) is as follows and includes “code first”, “code also”, and “use additional code” guidance:
History, Encounter, and Screenings
Some new codes have been added which allow for better tracking of COVID and post-COVID encounters. Note that the screening code (Z11.52) is for asymptomatic individuals. Symptomatic patients would use other codes (e.g., U07.1)
The following are the new codes:
Z11.52 Encounter for screening for COVID-19
Z20.822 Contact with and (suspected) exposure to COVID19
Contact with and (suspected) exposure to SARSCoV-2
Z86.16 Personal history of COVID-19
It is recommended that organizations carefully review the new official ICD-10-CM Guidelines (see References below) to understand government expectations for their use. Also in the References section below is a link to an article discussing the new Z86.16 code.
ICD-10-PCS Code Updates for January 1st
There are some new ICD-10-PCS codes which became effective on January 1, 2021. Due to advancement in the treatment of COVID-19, ICD-10-PCS code updates have not been following the regularly scheduled update calendar. Be sure your organization is prepared to also include the following:
NEW COVID ICD-10-PCS Codes -- January 2021
Section X New Technology
Body System W Anatomical Regions
Operation 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, orprophylactic substance except blood or blood productsBody Part
Approach
Device / Substance / Technology
Qualifier
1 Subcutaneous Tissue
3 Percutaneous
H Other New TechnologyMonoclonal Antibody
K Leronlimab MonoclonalAntibody
S COVID-19 Vaccine Dose1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine6 New Technology Group 6
2 Muscle
3 Percutaneous
S COVID-19 Vaccine Dose1
T COVID-19 Vaccine Dose 2
U COVID-19 Vaccine6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
E Etesevimab MonoclonalAntibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
F Bamlanivimab MonoclonalAntibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
G REGN-COV2 MonoclonalAntibody
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
H Other New Technolo
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
L CD24FcImmunomodulator
6 New Technology Group 6
3 Peripheral Vein
3 Percutaneous
3 Durvalumab Antineoplastic
6 New Technology Group 6
4 Central Vein
3 Percutaneous
E Remdesivir Anti-infective
6 New Technology Group 6
4 Central Vein
3 Percutaneous
F Bamlanivimab MonoclonalAntibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
G REGN-COV2 MonoclonalAntibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
H Other New TechnologyMonoclonal Antibody
6 New Technology Group 6
4 Central Vein
3 Percutaneous
L CD24FcImmunomodulator
6 New Technology Group 6
D Mouth and Pharynx
X External
M Baricitinib
6 New Technology Group 6
G Upper GI
H Lower GI7 Via Natural orArtificial Opening
M Baricitinib
6 New Technology Group 6
Note that new ICD-10-PCS codes added outside the regular update schedule are still flagged as New.
References/Resources
About Wyn Staheli, Director of Content - innoviHealth
Wyn Staheli is the Director of Content Research for innovHealth. She has over 30 years of experience in the healthcare industry. With her degree in Management Information Systems (MIS), she has been a programmer for a large insurance carrier as well as a California hospital system. She is also the author and editor of many medical resource books and the founder of InstaCode Institute.